scholarly journals Deep Vein Thrombosis, Raynaud's Phenomenon, and Prinzmetal Angina in a Patient with Glanzmann Thrombasthenia

2012 ◽  
Vol 2012 ◽  
pp. 1-4 ◽  
Author(s):  
Alan Nurden ◽  
Patrick Mercié ◽  
Pascal Zely ◽  
Paquita Nurden
Keyword(s):  
Deep Vein Thrombosis ◽  
Raynaud’S Phenomenon ◽  
Vascular Diseases ◽  
Later Life ◽  
Raynaud's Phenomenon ◽  
Severe Bleeding ◽  
Type I ◽  
Glanzmann Thrombasthenia ◽  
Vein Thrombosis ◽  
Deep Vein

Patients with Glanzmann thrombasthenia fail to form large platelet thrombi due to mutations that affect the biosynthesis and/or function of theαIIbβ3 integrin. The result is a moderate to severe bleeding syndrome. We now report unusual vascular behaviour in a 55-year-old woman with classic type I disease (with no plateletαIIbβ3 expression) and a homozygousITGA2Bmissense mutation (E324K) affecting the terminalβ-propeller domain ofαIIb. While exhibiting classic bleeding symptoms as a child, in later life this woman first developed deep vein thrombosis after a long air flight then showed vascular problems characteristic of Raynaud’s phenomenon, and finally this year she presented with chest pains suggestive of coronary heart disease. Yet while coronary angiography first showed a stenosis, this was not seen on a second examination when she was diagnosed with coronary spastic angina and Prinzmetal phenomenon. It is significant that the absence of platelet aggregation with physiologic agonists had not prevented any of the above cardiovascular or vascular diseases.

scholarly journals One novel and one recurrent mutation in the PROS1 gene cause type I protein S deficiency in patients with pulmonary embolism associated with deep vein thrombosis

2006 ◽  
Vol 81 (10) ◽  
pp. 787-797 ◽  
Author(s):  
Kazuhiro Mizukami ◽  
Toru Nakabayashi ◽  
Sumiyoshi Naitoh ◽  
Mika Takeda ◽  
Takashi Tarumi ◽  
...  
Keyword(s):  
Pulmonary Embolism ◽  
Deep Vein Thrombosis ◽  
Protein S ◽  
Recurrent Mutation ◽  
Type I ◽  
Protein S Deficiency ◽  
Vein Thrombosis ◽  
S Deficiency ◽  
Deep Vein

scholarly journals Registry of deep vein thrombosis patients hospitalized at the Department of Vascular Diseases, University Hospital Centre Zagreb

2018 ◽  
Vol 13 (11-12) ◽  
pp. 450-451
Author(s):  
Ljiljana Banfić ◽  
Majda Vrkić Kirhmajer ◽  
Mislav Puljević ◽  
Zoran Miovski ◽  
Krešimir Putarek ◽  
...  
Keyword(s):  
Deep Vein Thrombosis ◽  
Vascular Diseases ◽  
University Hospital ◽  
Vein Thrombosis ◽  
Deep Vein

scholarly journals Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases

Nutrients ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 2031
Author(s):  
Giuseppe Gallelli ◽  
Giulio Di Mizio ◽  
Caterina Palleria ◽  
Antonio Siniscalchi ◽  
Paolo Rubino ◽  
...  
Keyword(s):  
Deep Vein Thrombosis ◽  
Vascular Surgery ◽  
Venous Insufficiency ◽  
Life Support ◽  
Real Life ◽  
Vascular Diseases ◽  
Vein Thrombosis ◽  
Protease Enzyme ◽  
Superficial Vein Thrombosis ◽  
Deep Vein

Nattokinase (NK) is a serine protease enzyme with fibrinolytic activity. Even if it could be used for the treatment of several diseases, no data have been published supporting its use patients who underwent vascular surgery. In this study, we evaluated both the efficacy and the safety of nattokinase (100 mg/day per os) in patients admitted to vascular surgery. Patients were of both sexes, >18 years of age, with vascular diseases (i.e., deep vein thrombosis, superficial vein thrombosis, venous insufficiency), and naïve to specific pharmacological treatments (anticoagulants or anti-platelets). Patients were divided into three groups. Group 1: patients with deep vein thrombosis, treated with fondaparinux plus nattokinase. Group 2: patients with phlebitis, treated with enoxaparin plus nattokinase. Group 3: patients with venous insufficiency after classical surgery, treated with nattokinase one day later. During the study, we enrolled 153 patients (age 22–92 years), 92 females (60.1%) and 61 males (39.9%;), and documented that nattokinase was able to improve the clinical symptoms (p < 0.01) without the development of adverse drug reactions or drug interactions. Among the enrolled patients, during follow-up, we did not record new cases of vascular diseases. Attention to patients’ clinical evolution, monitoring of the INR, and timely and frequent adjustment of dosages represent the cornerstones of the safety of care for patients administered fibrinolytic drugs as a single treatment or in pharmacological combination. Therefore, we can conclude that the use of nattokinase represents an efficient and safe treatment able to both prevent and treat patients with vascular diseases.

scholarly journals INCIDENCE OF DEEP VEIN THROMBOSIS IN FLOATING KNEE

2021 ◽  
Vol 29 (1) ◽  
pp. 17-20
Author(s):  
JONATAS BRITO DE ALENCAR NETO ◽  
RÉJELOS CHARLES AGUIAR LIRA ◽  
RAFAEL DA SILVA CAVALCANTE ◽  
MARCIO BEZERRA GADELHA LOPES ◽  
CLODOALDO JOSÉ DUARTE DE SOUSA ◽  
...  
Keyword(s):  
Deep Vein Thrombosis ◽  
Medical Records ◽  
Emergency Treatment ◽  
Femoral Fractures ◽  
Tibial Fractures ◽  
Type I ◽  
Level Of Evidence ◽  
Vein Thrombosis ◽  
Compound Fractures ◽  
Deep Vein

ABSTRACT Objective: To report the incidence of deep vein thrombosis (DVT) in ipsilateral femur and tibial fractures (floating knee). Methods: This is a retrospective, analytical, observational study conducted with the medical records of thirty patients admitted to a trauma hospital between October 2016 and July 2017 with floating knee. Results: Patients aged between 21-30 years were the most affected by the condition (36%). Seventeen patients affected the dominant limb (57%); 19 (63%) patients were classified as Fraser type I, 18 (60%) had open (compound) fractures, 16 (53%) tibial fractures, and 8 (26%) femoral fractures. External fixation of the femur and tibia (25 patients = 83%) was the most common emergency treatment. In total, 17% of patients presented deep venous thrombosis (p = 0.409). Conclusion: Despite antithrombotic prophylaxis, the incidence of DVT in the affected limb of patients with floating knee was high. We found patients with Fraser I fractures, male, and with fractures in the non-dominant limb to present a higher chance of developing DVT. Level of Evidence III, Comparative retrospective study .

scholarly journals Relationship Between the Incidence of Deep Vein Thrombosis During Hospitalization and the Energy of Injury in Tibial Plateau Fractures

2020 ◽  
Vol 26 ◽  
pp. 107602962091394
Author(s):  
Li Jiahao ◽  
Zhang Kun ◽  
Zhang Binfei ◽  
Zhuang Yan ◽  
Xue Hanzhong ◽  
...  
Keyword(s):  
Deep Vein Thrombosis ◽  
Tibial Plateau ◽  
High Energy ◽  
Tibial Plateau Fractures ◽  
Low Energy ◽  
Type I ◽  
Vein Thrombosis ◽  
Energy Group ◽  
Energy Type ◽  
Deep Vein

This study aimed to investigate the relationship between the incidence of deep vein thrombosis (DVT) during hospitalization and the energy of injury in tibial plateau fractures (TPFs). One hundred and forty patients were enrolled between September 1, 2014, and October 1, 2017. According to Schatzker’s classification, they were classified into the low-energy (type I-III) and high-energy (type IV-VI) groups. For DVT evaluation, duplex ultrasonography was performed in the lower extremities preoperatively and postoperatively. The location and changes of DVT were recorded. All patients underwent mechanical and chemical thromboprophylaxis. The incidence of DVT in TPFs was 36.43% and 46.43% preoperatively and postoperatively, respectively. The DVT incidence was 31.75% (20/63) in the low-energy group and 40.26% (31/77) in the high-energy group preoperatively, and 44.44% (28/63) in the low-energy group and 48.05% (37/77) in the high-energy group postoperatively. There was no significant difference between the 2 groups preoperatively ( P = .298) and postoperatively ( P = .785). The days between operation and discharge ( P = .016), blood loss during surgery ( P = .016), and preoperative d-dimer level ( P = .02) showed differences between the 2 groups. Additionally, 29 new thrombi (14 [48.28%] in the high-energy group and 15 [51.72%] in the low-energy group) appeared and 16 preoperative thrombi disappeared postoperatively. Despite mechanical and chemical thromboprophylaxis, the DVT risk in patients with TPFs remains high. Although the DVT incidence is not significantly different between high-energy and low-energy injuries, the occurrence of DVT should be carefully monitored.

Sign in / Sign up

Export Citation Format

Share Document